Journals (beta)
Posted by kinasepro on August 21, 2008
The 15M Pharmacopeia and Cephalon deal from a couple years ago was likely for compounds like these c-Met / Alk inhibitors:
O=C(NC)C1=CC=CC(F)=C1NC2=NC(NC3=CC=C4C(C)(C)CC(NCCOC)CNC4=C3)=NC=C2Cl
yeh, its 1300 pages and I know they’re old, but I got some catching up to do…
Posted in c-Met, Cephalon, Pharmacopeia | Leave a Comment »
Posted by kinasepro on March 27, 2007
Schering-Plough has a series of CDK inhibitors of which the latest installment is: US20070066621. Earlier app’s in this series appear as a combined effort via SP and PCOP, and Pharmacopeia has a press release suggesting that the collaboration has an oncology candidate in Ph1. Hrmph, No ph1 oncology trials via ScheringP in the US and the press on this stuff is a little thin.
Vernalis described related series’ in Bioorg Med Chem Lett ’05, 863; 1Y8Y 1Y91 and Bioorg Med Chem Lett ’06, 1353; 2C68, 2C69, 2C6T, 2C6O, 2C6M, 2C6L, 2C6K, 2C6I
Posted in CDK2, Pharmacopeia, Schering-Plough | Leave a Comment »
Posted by kinasepro on December 30, 2006
via Jak3 but of course – in an underanounced deal with Pharmacopeia:
…Wyeth will pay Pharmacopeia $5 million initially, as much as $9 million of research funding over the next three years, and as much as $175 million for reaching certain goals with the JAK3 kinase inhibitor drug.
While it’s likely they have a few which haven’t published yet, WO/2006/108103 is the most recent PCOP Jak3 application.
![O=C1NC2=C(N=C(N3C4=CC(F)=CC=C4N=C3)N=C2)N1[C@H]5CCC(C6=C5C=CC=C6)=O](http://img174.imageshack.us/img174/9469/jak3pcopqw2.jpg)
They’ve been at this stuff for a while – I reckon since WO/2001/047921 and have a recent Tet Lett on a related series. Check 2HK5 for a clue on how they bind.
>> update 1/25/07 >> US20070021443 Jak3 Pharmacopeia patent application
Posted in Deals, JAK, Pharmacopeia, Wyeth | 3 Comments »
